Biogen Idec Takes Option To MAKScientific MS Program
BOSTON,
March 14, 2012 /PRNewswire/ -- MAKScientific, LLC, a privately held company focused on the discovery of novel therapeutics modulating cannabinoid pathways, today announced that it has entered into an exclusive, worldwide option and collaboration agreement with Biogen Idec (NASDAQ: BIIB) to develop and commercialize drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.
Under the agreement, Biogen Idec will receive an option for an exclusive license to select discovery-stage MAKScientific drug candidates for all indications worldwide. Upon Biogen Idec's exercise of the option, MAKScientific will be eligible to receive an exercise fee of up to $3 million and up to an additional $31 million in milestone payments associated with the clinical development of the drug candidates. In addition, MAKScientific will be eligible to receive royalties on net sales worldwide.
"We are very excited to initiate this collaboration with Biogen Idec," said Alexandros Makriyannis, PhD, Founder of MAKScientific. "We believe it will help advance our proprietary medicinal chemistry to the benefit of MS patients. As a global leader in MS research and development, Biogen Idec is the ideal partner for our discovery and development program."
About MAKScientific.
MAKScientific LLC, is a privately held, Massachusetts-based, discovery stage, life sciences company specializing in the identification and development of novel therapies exploiting cutting-edge cannabinoid receptor pathways for the treatment of pain, inflammatory disorders and MS. SOURCE MAKScientific, LLC
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
